Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C61606
http://purl.obolibrary.org/obo/NCIT_C61606
|
|---|---|
| Preferred Name | Atrasentan |
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| prefLabel | Atrasentan
|
|---|---|
| label | Atrasentan
|
| Has_Salt_Form | |
| code | C61606
|
| prefixIRI | NCIT:C61606
|
| in_subset | |
| Preferred_Name | Atrasentan
|
| FDA_UNII_Code | V6D7VK2215
|
| Contributing_Source | FDA
|
| Chemical_Formula | C29H38N2O6
|
| CAS_Registry | 173937-91-2
|
| Legacy Concept Name | Atrasentan_Base
|
| type | |
| ALT_DEFINITION | A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists.
|
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C0935914
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |